Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 1,581–1,590 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1581

    Medicine slug
    trilaciclib
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 1130 L

      Numeric value
      1,130
      Unit
      L
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3179c19-78f3-4bf1-b73e-7f7638522ab1 (opens source in a new tab)

        Trilaciclib label

        Version not recorded · Effective date not recorded

        The volume of distribution at steady state was 1130 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b06922c-498d-4871-a037-84a44e6a6b6c (opens source in a new tab)

        Trilaciclib label

        Version not recorded · Effective date not recorded

        The volume of distribution at steady state was 1130 L.

  2. Projected row 1582

    Medicine slug
    trimethobenzamide
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 100%

      Numeric value
      100
      Unit
      %
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7da90678-b229-4ad6-9193-2b8a3e9ba695 (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        The relative bioavailability of the capsule formulation compared to the solution is 100%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9a661ca-87ca-4c96-88ef-58fcaae233b5 (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        The relative bioavailability of the capsule formulation compared to the solution is 100%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:147def93-cd3d-4e42-89ad-6a6b413bf362 (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        The relative bioavailability of the capsule formulation compared to the solution is 100%.

  3. Projected row 1583

    Medicine slug
    trimethobenzamide
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    7
    Agreement rate
    1
    Recorded readings

    1. 7 to 9 hours

      Numeric value
      7
      Unit
      hours
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0aa9b7e-bbe7-482e-81d3-d9658d5ac21f (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of trimethobenzamide is 7 to 9 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7da90678-b229-4ad6-9193-2b8a3e9ba695 (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of trimethobenzamide is 7 to 9 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee626da9-cffc-4bb9-a528-482687201b2a (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of trimethobenzamide is 7 to 9 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00ba5395-1455-4ea9-9278-e3749979526c (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of trimethobenzamide is 7 to 9 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9a661ca-87ca-4c96-88ef-58fcaae233b5 (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of trimethobenzamide is 7 to 9 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c18073be-d52a-4347-a8d1-6be11bcb7824 (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of trimethobenzamide is 7 to 9 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:147def93-cd3d-4e42-89ad-6a6b413bf362 (opens source in a new tab)

        Trimethobenzamide label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of trimethobenzamide is 7 to 9 hours.

  4. Projected row 1584

    Medicine slug
    trimethoprim
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 8 to 10 hours

      Numeric value
      8
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:249e938d-f181-47c4-a082-372d65462f33 (opens source in a new tab)

        Trimethoprim label

        Version not recorded · Effective date not recorded

        The half-life of trimethoprim ranges from 8 to 10 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:73ccebc1-7412-2424-d62c-a5180ec52d81 (opens source in a new tab)

        Trimethoprim label

        Version not recorded · Effective date not recorded

        The half-life of trimethoprim ranges from 8 to 10 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95a1572c-6109-4d1f-bf92-262015a7654e (opens source in a new tab)

        Trimethoprim label

        Version not recorded · Effective date not recorded

        The half-life of trimethoprim ranges from 8 to 10 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f756f4be-3cda-ab98-e053-6294a90a1424 (opens source in a new tab)

        Trimethoprim label

        Version not recorded · Effective date not recorded

        The half-life of trimethoprim ranges from 8 to 10 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b27e43b5-670b-43f6-b28b-413e54f914da (opens source in a new tab)

        Trimethoprim label

        Version not recorded · Effective date not recorded

        The half-life of trimethoprim ranges from 8 to 10 hours.

  5. Projected row 1585

    Medicine slug
    ulipristal
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 0.75 hours

      Numeric value
      0.75
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e5f09468-7ac8-40ba-a85b-758a32f586c3 (opens source in a new tab)

        Ulipristal label

        Version not recorded · Effective date not recorded

        1/2 = elimination half-life * Median (range) Effect of food: Administration of ella together with a high-fat breakfast resulted in approximately 40 - 45% lower mean C max , a delayed t max (from a median of 0.75 hours to 3 hours) and 20 - 25% higher mean AUC 0-∞ of ulipristal acetate and monodemethyl-ulipristal acetate compared with administration in the fasting state.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2bf93d23-cddd-4613-9066-5b5fa090404b (opens source in a new tab)

        Ulipristal label

        Version not recorded · Effective date not recorded

        1/2 = elimination half-life * Median (range) Effect of food: Administration of ella together with a high-fat breakfast resulted in approximately 40 - 45% lower mean C max , a delayed t max (from a median of 0.75 hours to 3 hours) and 20 - 25% higher mean AUC 0-∞ of ulipristal acetate and monodemethyl-ulipristal acetate compared with administration in the fasting state.

  6. Projected row 1586

    Medicine slug
    umeclidinium
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 11 hours

      Numeric value
      11
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbb64747-1505-49d7-9a33-99dd402e96d3 (opens source in a new tab)

        Umeclidinium label

        Version not recorded · Effective date not recorded

        Excretion: The effective half-life after once-daily orally inhaled dosing is 11 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:763388a5-cc89-4c25-8562-521df679b7e8 (opens source in a new tab)

        Umeclidinium label

        Version not recorded · Effective date not recorded

        Excretion : The effective half-life after once-daily orally inhaled dosing is 11 hours.

  7. Projected row 1587

    Medicine slug
    umeclidinium
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 89%

      Numeric value
      89
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbb64747-1505-49d7-9a33-99dd402e96d3 (opens source in a new tab)

        Umeclidinium label

        Version not recorded · Effective date not recorded

        In vitro plasma protein binding in human plasma was on average 89%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:763388a5-cc89-4c25-8562-521df679b7e8 (opens source in a new tab)

        Umeclidinium label

        Version not recorded · Effective date not recorded

        In vitro plasma protein binding in human plasma was on average 89%.

  8. Projected row 1588

    Medicine slug
    umeclidinium
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 86 L

      Numeric value
      86
      Unit
      L
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbb64747-1505-49d7-9a33-99dd402e96d3 (opens source in a new tab)

        Umeclidinium label

        Version not recorded · Effective date not recorded

        Distribution Following intravenous administration to healthy subjects, the mean volume of distribution was 86 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:763388a5-cc89-4c25-8562-521df679b7e8 (opens source in a new tab)

        Umeclidinium label

        Version not recorded · Effective date not recorded

        Distribution Following intravenous administration to healthy subjects, the mean volume of distribution was 86 L.

  9. Projected row 1589

    Medicine slug
    uridine-triacetate
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 2 to 2.5 hours

      Numeric value
      2
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:269f7363-63ed-444e-85f1-f0009e44818b (opens source in a new tab)

        Uridine Triacetate label

        Version not recorded · Effective date not recorded

        Maximum concentrations of uridine in plasma following oral VISTOGARD are generally achieved within 2 to 3 hours, and the half-life ranges from approximately 2 to 2.5 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88ca4d2b-3905-474b-9fd6-c81474f2fb4b (opens source in a new tab)

        Uridine Triacetate label

        Version not recorded · Effective date not recorded

        Maximum concentrations of uridine in plasma following oral XURIDEN are generally achieved within 2 to 3 hours, and the half-life ranges from approximately 2 to 2.5 hours.

  10. Projected row 1590

    Medicine slug
    ustekinumab
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 19 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23b486eb-f48d-47d4-815e-1313d4ebfbfa (opens source in a new tab)

        Ustekinumab label

        Version not recorded · Effective date not recorded

        Population pharmacokinetic analyses showed that the clearance of ustekinumab was 0.19 L/day (95% CI: 0.185, 0.197) in subjects with Crohn's disease and 0.19 L/day (95% CI: 0.179, 0.192) in subjects with ulcerative colitis with an estimated median terminal half-life of approximately 19 days for both IBD (Crohn's disease and ulcerative colitis) populations.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c77a9664-e3bb-4023-b400-127aa53bca2b (opens source in a new tab)

        Ustekinumab label

        Version not recorded · Effective date not recorded

        Population pharmacokinetic analyses showed that the clearance of ustekinumab was 0.19 L/day (95% CI: 0.185, 0.197) in subjects with Crohn's disease and 0.19 L/day (95% CI: 0.179, 0.192) in subjects with ulcerative colitis with an estimated median terminal half-life of approximately 19 days for both IBD (Crohn's disease and ulcerative colitis) populations.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=1580

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy